Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis
Pancreatology · 2026
DOI: 10.1016/j.pan.2026.04.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pancreatology, 2026. Verfasst von Gaetano Lauri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research, Center, IRCCS San Raffaele Scientific Instit…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: European Commission.
Abstract (Originalsprache)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for glucose control and weight management. Concerns have arisen regarding a potential association with pancreatic ductal adenocarcinoma (PDAC), though evidence remains conflicting. We performed a systematic review and meta-analysis to evaluate PDAC risk in GLP-1 RA users. METHODS: We included studies with ≥24 weeks of follow-up assessing PDAC incidence in patients treated with GLP-1 RAs. Eligible studies included adults with type 2 diabetes or obesity. Pooled estimates were calculated using random-effects models. Heterogeneity was assessed with I2, publication bias with Egger's test, and meta-regression explored potential effect modifiers. RESULTS: Sixty studies (49 randomized trials and 11 observational cohorts) including 4,932,290 patients (2,281,546 GLP-1 RA users; 2,650,744 non-users) were analyzed. GLP-1 RA use was not associated with an increased PDAC risk overall (OR 0.688, 95% CI 0.575-0.824; I2 = 69.4%). An inverse association was observed mainly in observational cohorts, in overweight/obese patients with diabetes, and with prolonged exposure (>52 weeks) and follow-up (>60 weeks). Meta-regression confirmed treatment duration and indication as significant modifiers. Egger's test (p = 0.829) excluded publication bias. CONCLUSIONS: GLP-1 RA therapy was not associated with an increased risk of PDAC. Observational data suggest a possible inverse association, although further high-quality studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research, Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
- Department of Experimental Medicine, Università del Salento, Lecce, Italy.
- Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research, Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: tacelli.matteo@hsr.it.
Förderung
- European Commission
Zitieren
APA
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026). Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Pancreatology. https://doi.org/10.1016/j.pan.2026.04.005
Vancouver
Lauri G, Arcidiacono PG, Facciorusso A, Capurso G, Tacelli M. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Pancreatology. 2026. doi:10.1016/j.pan.2026.04.005
BibTeX
@article{Lauri2026,
author = {Lauri, Gaetano and Arcidiacono, Paolo Giorgio and Facciorusso, Antonio and Capurso, Gabriele and Tacelli, Matteo},
title = {Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis},
journal = {Pancreatology},
year = {2026},
doi = {10.1016/j.pan.2026.04.005}
}
EUVIMED